328 results on '"Haycox, Alan"'
Search Results
2. What Is Cost-Minimisation Analysis?
3. Some Problems/Assumptions in Pharmacoeconomic Analysis
4. Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies
5. Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study
6. Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications
7. Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial
8. A Single-Center Randomized Trial of Intraoperative Zero-Balanced Ultrafiltration During Cardiopulmonary Bypass for Patients With Impaired Kidney Function Undergoing Cardiac Surgery
9. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
10. Foley Catheterisation Versus Oral Misoprostol for Induction of Labour in Hypertensive Women in India (INFORM): A Multicentre, Open-Label, Randomised Controlled Trial
11. PO232 Incidence and healthcare costs of viral meningitis in adults – a multicentre prospective observational study in england
12. Through a Glass Darkly: Economics and Personalised Medicine
13. Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries?
14. Why Cancer?
15. Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies
16. Systematic Review Of Cost Effectiveness Studies Of Telemedicine Interventions
17. An Integrated National Pharmaceutical Policy For The United Kingdom?
18. Importance of Health Economics Must Be Recognised When Trials Are Designed
19. Clinical Guidelines: The Hidden Costs
20. Treatment of Gastro-Oesophageal Reflux Disease in Adults
21. The cost effectiveness of renal provision in the UK
22. Referee report. For: Clinical and economic benefits of the Intellispace Portal applications CT TAVI and Spectral CT: Findings from a two-step Delphi panel [version 1; peer review: 1 approved]
23. Estimating the Relationship between Preference-Based Generic Utility Instruments and Disease-Specific Quality-of-Life Measures in Severe Chronic Constipation: Challenges in Practice
24. Influence of patient co-payments on atypical antipsychotic choice in Poland: Implications once generic atypicals are available
25. Cost Effectiveness Of Lowering Cholesterol [with Reply]
26. Ongoing pharmaceutical reforms in France: Implications for key stakeholder groups
27. Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK Setting: An Economic Markov Model Evaluation
28. Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe
29. Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies
30. Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectiveness models
31. Insulin Aspart: An Evidence-Based Medicine Review
32. How Much Should the NHS Pay for a QALY?
33. Accounting for Noncompliance in Pharmacoeconomic Evaluations
34. The Impact of Health Economics on Healthcare Delivery: The Health Economists’ Perspective
35. What Is Cost- Minimization Analysis?
36. European countries with small populations can obtain low prices for drugs: Lithuania as a case history
37. Pharmaceutical policy and market in Iran: past experiences and future challenges
38. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs
39. Customising an International Disease Management Model to the Needs of Individual Countries: Application to Upper Gastrointestinal Disease
40. Development of an Economic Model for the Management of Upper Gastrointestinal Disease in Primary Care: Preliminary Findings
41. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications
42. Does ‘NICE blight’ exist, and if so, why?
43. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction
44. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance
45. Drug Rationing in the UK National Health Service: Current Status and Future Prospects
46. Generic olanzapine: health authority opportunity or nightmare?
47. Insight into recent reforms and initiatives in Austria: implications for key stakeholders
48. Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans
49. Pricing of oral generic cancer medicines in 25 European countries; findings and implications
50. When NICE Says No!
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.